Skip to search formSkip to main contentSkip to account menu

idarucizumab

Known as: aDabi-Fab 
National Institutes of Health

Related topics

Related topics

4 relations
50 ML idarucizumab 50 MG/ML Injection [Praxbind]antigen binding

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

Praxbind

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Removal of dabigatran using sorbent hemadsorption.
2019
2019
Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery
Supplemental Digital Content is available in the text Objective: To further examine anticoagulation reversal and clinical… 
2018
2018
Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience
BackgroundIdarucizumab is used to reverse the effects of dabigatran. Information on the use of idarucizumab in the clinical… 
2018
2018
Incomplete dabigatran reversal with idarucizumab
Abstract Context: With increasing use of direct oral anticoagulants (DOACs), urgent reversal of these agents becomes a growing… 
2018
2018
Assessment of patients post reversal with idarucizumab
Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran’s anticoagulant activity… 
2017
2017
The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.
PURPOSE To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban… 
2016
2016
Usual Blood Pressure and New-Onset Diabetes Risk: Evidence From 4.1 Million Adults and a Meta-Analysis.
Review
2016
Review
2016
Idarucizumab (Praxbind) Formulary Review.
Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug… 
Review
2016
Review
2016
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Review
2015
Review
2015
Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy
Despite favourable results in pivotal clinical trials involving novel direct oral anticoagulants, vitamin K antagonists remain… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)